MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Daiichi Sankyo CO Ltd Ord (OP:DSKYF)

18.17 +1.22 (+7.19%)
Streaming Delayed Price Updated: 1:56 PM EDT, Aug 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,328
Open 18.17
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 16.95
Today's Range 18.10 - 18.26
52wk Range 13.85 - 29.15
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer
BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster... 
Via MarketMinute
Topics Intellectual Property
News headline image
The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape
As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property

Performance

YTD
-17.4%
-17.4%
1 Month
+6.7%
+6.7%
3 Month
+6.6%
+6.6%
6 Month
-7.0%
-7.0%
1 Year
-26.7%
-26.7%

More News

Read More
News headline image
Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact ↗
Via Benzinga
News headline image
FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer ↗
Via Benzinga
News headline image
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients ↗
Via Benzinga
News headline image
FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients ↗
Via Benzinga
News headline image
FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients ↗
Via Benzinga
News headline image
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer ↗
Via Benzinga
News headline image
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients ↗
Via Benzinga
News headline image
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial ↗
Via Benzinga
News headline image
Week In Review: Curon Out-Licenses T-Cell-Engager To Merck For $700 Million Upfront ↗
Via Talk Markets
News headline image
Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10 ↗
Via Benzinga
News headline image
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast ↗
Via Benzinga
News headline image
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug ↗
Via Benzinga
News headline image
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More ↗
Via Benzinga
News headline image
Why Is AstraZeneca Stock Trading Lower On Tuesday? ↗
Via Benzinga
News headline image
Double Good News For AstraZeneca's Breast Cancer Drugs ↗
Via Benzinga
News headline image
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor ↗
Via Benzinga
News headline image
What's Going On With Pfizer Stock Today? ↗
Via Benzinga
News headline image
Merck Signs Multi-Billion Deal With Japan's Daiichi Sankyo For Cancer Therapy Drug Development ↗
Via Benzinga
News headline image
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting ↗
Via Benzinga
News headline image
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials ↗
Via Benzinga
News headline image
FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt ↗
Via Benzinga
News headline image
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial ↗
Via Benzinga
News headline image
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting ↗
Via Benzinga

Frequently Asked Questions

Is Daiichi Sankyo CO Ltd Ord publicly traded?
Yes, Daiichi Sankyo CO Ltd Ord is publicly traded.
What exchange does Daiichi Sankyo CO Ltd Ord trade on?
Daiichi Sankyo CO Ltd Ord trades on the OTC Traded
What is the ticker symbol for Daiichi Sankyo CO Ltd Ord?
The ticker symbol for Daiichi Sankyo CO Ltd Ord is DSKYF on the OTC Traded
What is the current price of Daiichi Sankyo CO Ltd Ord?
The current price of Daiichi Sankyo CO Ltd Ord is 18.17
When was Daiichi Sankyo CO Ltd Ord last traded?
The last trade of Daiichi Sankyo CO Ltd Ord was at 08/28/26 01:56 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story